

해외 바이오의약품 임상 현황 ('22년 12월 3주)

한국바이오의약품협회, 2022.12.27.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2022.12.19. ~ 2022.12.25.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05541250	Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)	Biological: Autologous Human Schwann Cell	W. Dalton Dietrich United States Department of Defense University of Miami	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05541250
NCT05536349	Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)	Drug: Pirtobrutinib Drug: Obinutuzumab Drug: Venetoclax Drug: Valacyclovir Drug: Allopurinol	M.D. Anderson Cancer Center Loxo Oncology, Inc. The Leukemia and Lymphoma Society	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05536349
NCT05176366	Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis	Drug: ExoFlo	Direct Biologics, LLC	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05176366
NCT05130983	A Phase I Study of ExoFlo, an ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Medically Refractory Crohn's Disease	Drug: Bone Marrow MSC Derived Extracellular Vesicle Isolate	Direct Biologics, LLC	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05130983
NCT05660772	A Randomized, Multi-center, Double Blind, Parallel Study to Examine the Effect of Lipogems Processed Microfragmented Adipose Tissue in Comparison to Corticosteroid for the Treatment of Knee Osteoarthritis	Device: Microfragmented Adipose Tissue Drug: Corticosteroid	Lipogems International spa Alira Health	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05660772
NCT05631327	A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors	Drug: JZP341	Jazz Pharmaceuticals	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05631327

○ 중국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05663086	Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above (Negative Antibody Against COVID-19)	Biological: One dose group Biological: Two doses group Biological: Aged 18-59 years Biological: Aged 60 years old and above	Guangzhou Patronus Biotech Co., Ltd. Yantai Patronus Biotech Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05663086
NCT05650216	Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC (NICE-RT)	Drug: Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2) , Immunotherapy (camrelizumab 200mg) , Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy , distant lymph node 0.5Gy*4)	Shanghai Chest Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05650216
NCT05622942	Phase Ib Clinical Trial of Recombinant Pneumococcal Protein Vaccine	Biological: PBPV Biological: PPV23	CanSino Biologics Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05622942
NCT05512351	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma	Drug: Tislelizumab plus Bevacizumab	Henan Provincial People's Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05512351
NCT05268172	IFN- γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites	Drug: IFN- γ and CIK cells, Tcm cells or CAR T cells	Affiliated Hospital of Jiangnan University Sichuan University Zhejiang Provincial People's Hospital Hunan Cancer Hospital West China Hospital Wuxi People's Hospital Shenzhen Second People's Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05268172

해외 바이오의약품 임상 현황 ('22년 12월 3주)

한국바이오의약품협회, 2022.12.27.

NCT05565807	Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma	Biological: STI-6129	Zhejiang ACEA Pharmaceutical Co. Ltd.	Phase 1 Phase 2	
NCT05564052	A Study of Ibrutinib With Rituximab in Relapsed/Refractory Mantle Cell Lymphoma	Drug: Ibrutinib Drug: Lenalidomide Drug: Rituximab Drug: Bortezomib	Janssen Research & Development, LLC Pharmacyclics LLC.	Phase 2 Phase 3	